您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Forphenicinol
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Forphenicinol
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Forphenicinol图片
CAS NO:71522-58-2
包装与价格:
包装价格(元)
500 µg电议
1mg电议

产品介绍
An immunomodulator and a derivative of forphenicine
Cas No.71522-58-2
Canonical SMILESOC([C@H](C1=CC(O)=C(C=C1)CO)N)=O
分子式C9H11NO4
分子量197.2
溶解度DMSO: soluble,Methanol: soluble,Water: soluble
储存条件-20буC
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Forphenicinol is an immunomodulator and a derivative of the bacterial metabolite forphenicine .1It increases the phagocytosis of yeast by peritoneal macrophages isolated from thioglycolate-stimulated mice. Forphenicinol (100 µg/animal) prevents cyclophosphamide-induced suppression of delayed-type hypersensitivity (DTH), as well as enhances DTH in response to the hapten oxazolone or sheep red blood cells in mice. It enhances the bactericidal activity of macrophages againstP. aeruginosain mice when administered at a dose of 0.5 mg/kg.2Forphenicinol (15.6-1,000 µg/animal) increases survival in a mouse model ofP. aeruginosainfection.3It also inhibits tumor growth in S180 sarcoma and IMC carcinoma mouse xenograft models when administered at doses ranging from 0.05 to 5 mg/kg per day.

1.Ishizuka, M., Ishizeki, S., Masuda, T., et al.Studies on effects of forphenicinol on immune responsesJ. Antibiot. (Tokyo)35(8)1042-1048(1982) 2.Naito, K., Arakawa, H., Watanabe, Y., et al.Protective effect of forphenicinol, a low molecular weight immunomodifier, against infection with Pseudomonas aeruginosa in mice and its mechanismsJ. Antibiot. (Tokyo)40(4)547-545(1987) 3.Ishizuka, M., Masuda, T., Kanbayashi, N., et al.Antitumor effect of forphenicinol, a low molecular weight immunomodifier, on murine transplantable tumors and microbial infectionsJ. Antibiot. (Tokyo)35(8)1049-1054(1982)